Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Up 5.5% – What’s Next?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) was up 5.5% on Thursday. The company traded as high as GBX 480 and last traded at GBX 480. 6,344 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 23,572 shares. The stock had previously closed at GBX 455.

Hemogenyx Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 167.66, a current ratio of 1.38 and a quick ratio of 6.72. The firm has a market capitalization of £32.27 million, a P/E ratio of -2.78 and a beta of 1.49. The company’s 50 day moving average price is GBX 581.56 and its 200 day moving average price is GBX 741.15.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.